The role of palliative surgery in castration-resistant prostate cancer

Current Opinion in Supportive and Palliative Care

Volumn 8, Issue 3, 2014, Pages 250-257

  Piper, Charlotte ^a   Porres, Daniel ^a   Pfister, David ^a   Heidenreich, Axel ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Castration resistant prostate cancer; Continent vesicostomy; Detour system; Radical cystectomy; Radical prostatectomy; Subcutaneous pyelovesical bypass; Ureteral reimplantation

Indexed keywords

HUMAN; MALE; PALLIATIVE THERAPY; PROCEDURES; PROSTATECTOMY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; UROLOGIC SURGERY;

HUMANS; MALE; PALLIATIVE CARE; PROSTATECTOMY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; UROLOGIC SURGICAL PROCEDURES;

EID: 84905719493     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0000000000000078     Document Type: Review

References (37)

1. Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU Guidelines on Prostate Cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2014; 65:467.
2. Alemayehu B, Buysman E, Parry D, et al. Economic burden and healthcare utilization associated with castration-resistant prostate cancer in a commercial and Medicare Advantage US patient population. J Med Econ 2010; 13:351.
3. Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998; 339:1036.
4. Glass TR, Tangen CM, Crawford ED, et al. Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning. J Urol 2003; 169:164-169.
5. Hussain M, Tangen CM, Higano C, et al. Southwest Oncology Group Trial 9346 INT 0162. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 2006; 24:3984.
6. Won AC, Gurney H, Marx G, et al. Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer. BJU Int 2013; 112:E250.
7. Aus G, Hugosson XXJ, Norlén L. Need for hospital care and palliative treatment for prostate cancer treated with noncurative intent. J Urol 1995; 154 (2 Pt 1):466.
8. Tzelepi V, Efstathiou E, Wen S, et al. Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment. J Clin Oncol 2011; 29:2574.
9. Steinberg GD, Epstein JI, Piantadosi S, et al. Management of stage D1adenocarcinoma of the prostate: the Johns Hopkins experience 1974 to 1987. J Urol 1990; 144:1425.
10. Thompson IM, Tangen C, Basler J, Crawford ED. Impact of previous local treatment for prostate cancer on subsequent metastatic disease. J Urol 2002; 168:1008.
11. Gjertson C, Asher K, Sclar J, et al. Local control and long-term disease-free survival for stage D1 (T2-T4N1-N2M0) prostate cancer after radical prostatectomy in the PSA era. Urology 2007; 70:723.
12. Grimm M-O, Kamphausen H, Hugenschmidt H, et al. Clinical outcome of patients with lymph node positive prostate cancer after radical prostatectomy versus androgen deprivation. Eur Urol 2012; 41:628.
13. Qin XJ, Ma CG, Ye DW, et al. Tumor cytoreduction results in better response to androgen ablation-a preliminary report of palliative transurethral resection of the prostate in metastatic hormone sensitive prostate cancer. Urol Oncol 2012; 30:145.
14. Krupski TL, Stukenborg GJ, Moon K, Theodorescu D. The relationship of palliative transurethral resection of the prostate with disease progression in patients with prostate cancer. BJU Int 2010; 106:1477-1483.
15. Michielsen DP, Coomans D, Engels B, Braeckman JG. Bipolar versus monopolar technique for palliative transurethral prostate resection. Arch Med Sci 2010; 6:780-786.
16. Marszalek M, Ponholzer A, Rauchenwald M, Madersbacher S. Palliative transurethral resection of the prostate: functional outcome and impact on survival. BJU Int 2007; 99:56-59.
17. Pfister D, Epplen R, Porres-Knoblauch D, Heidenreich A. Possibilities for surgical correction of an anastomotic stricture after radical prostatectomy. Urologe A 2011; 50:1392-1395.
18. Kavanagh A, Afshar K, Scott H, MacNeily AE. Bladder neck closure in conjunction with enterocystoplasty and Mitrofanoff diversion for complex incontinence: closing the door for good. J Urol 2012; 188 (4 Suppl):1561-1565.
19. Veeratterapillay R, Morton H, Thorpe AC, Harding C. Reconstructing the lower urinary tract: The Mitrofanoff principle. Indian J Urol 2013; 29:316-321.
20. De E, Pisters LL, Pettaway CA, et al. Salvage prostatectomy with bladder neck closure, continent catheterizable stoma and bladder augmentation: feasibility and patient reported continence outcomes at 32 months. J Urol 2007; 177:2200-2204.
21. Pfister D, Porres D, Epplen R, et al. Palliative radical (cysto)prostatectomy in locally advanced castration-resistant prostate cancer. Urologe A 2011; 50:1101-1105.
22. Leibovici D, Kamat AM, Pettaway CA, et al. Cystoprostatectomy for effective palliation of symptomatic bladder invasion by prostate cancer. J Urol 2005; 174:2186-2190.
23. Kamat AM, Huang SF, Bermejo CE, et al. Total pelvic exenteration: effective palliation of perineal pain in patients with locally recurrent prostate cancer. J Urol 2003; 170:1868-1871.
24. Heidenreich A, Richter S, Thüer D, Pfister D. Prognostic parameters, complications, and oncologic and functional outcome of salvage radical prostatectomy for locally recurrent prostate cancer after 21st-century radiotherapy. Eur Urol 2010; 57:437-443.
25. Heidenreich A, Pfister D. Retroperitoneal lymphadenectomy and resection for testicular cancer: an update on best practice. Ther Adv Urol 2012; 4:187-205.
26. Chitale SV, Chitale VR. Bilateral ureterocutaneostomy with modified stoma: long-term follow-up. World J Urol 2006; 24:220-223.
27. MacGregor PS, Montie JE, Straffon RA. Cutaneous ureterostomy as palliative diversion in adults with malignancy. Urology 1987; 30:31-34.
28. Song HY, Kim CS, Jeong IG, et al. Placement of retrievable self-expandable metallic stents with barbs into patients with obstructive prostate cancer. Eur Radiol 2013; 23:780-785.
29. Zaman F, Poullis C, Bach C, et al. Use of a segmental thermoexpandable metal alloy stent in the management of malignant ureteric obstruction: a single centre experience in the UK. Urol Int 2011; 87:405-410.
30. Misra S, Coker C, Richenberg J. Percutaneous nephrostomy for ureteric obstruction due to advanced pelvic malignancy: have we got the balance right? Int Urol Nephrol 2013; 45:627-632.
31. Culkin DJ, Wheeler JS Jr, Marsans RE, et al. Percutaneous nephrostomy for palliation of metastatic ureteral obstruction. Urology 1987; 30:229-231.
32. Chiou RK, Chang WY, Horan JJ. Ureteral obstruction associated with prostate cancer: the outcome after percutaneous nephrostomy. J Urol 1990; 143:957-959.
33. Lienert A, Ing A, Mark S. Prognostic factors in malignant ureteric obstruction. BJU Int 2009; 104:938-941.
34. Kihl B, Bratt CG. Reimplantation of the ureter in prostatic carcinoma associated with bilateral ureteric obstruction. Br J Urol 1981; 53:349-352.
35. Heidenreich A, Ohlmann C, Braun M. Palliative subcutaneous urinary diversion in malignant ureteral obstruction (Detour system). Aktuelle Urol 2004; 35:429-441.
36. Lloyd SN, Tirukonda P, Biyani CS, et al. The detour extra-anatomic stent-a permanent solution for benign and malignant ureteric obstruction? Eur Urol 2007; 52:193-198.
37. Janitzky A, Borski J, Porsch M, et al. Long- term results for subcutaneous Detour® prosthesis for ureteral obstruction: experiences of implantation, aftercare and management of complications. Urologe A 2012; 51:1714-1721.